An Eye Warning on Every GLP-1 Label: What the FDA Actually Said
Share
If you're on a GLP-1 medication, you may have seen the headline this week: the FDA is requiring a new warning — about a rare eye condition — on the labels of every GLP-1 medication. Headlines like that can land hard when it's your health. So let's slow down and read what the FDA actually said.
What happened
After reviewing clinical trials, real-world patient data, and published studies, the FDA is requiring the makers of all GLP-1 medications to add a warning about a potential increased risk of a condition called NAION — nonarteritic anterior ischemic optic neuropathy. NAION happens when blood flow to the front part of the optic nerve decreases, and it can cause sudden vision loss, which can be permanent.
That's the serious part, and it's real. Here is the rest of the picture, which the headlines mostly skipped:
What the numbers actually say
- It is rare. Across an analysis of 126 trials with more than 134,000 patients, researchers found about 6.4 cases of NAION per 100,000 patient-years among GLP-1 users, compared with 3.8 among patients on other treatments or placebos.
- A cause-and-effect relationship has not been established. The FDA is adding a warning out of caution — that is what warnings are for — but the agency's own review does not show these medications cause NAION.
- Diabetes itself is a known risk factor for NAION, which makes the picture harder to read: many people taking GLP-1 medications have the very condition that raises NAION risk on its own.
- It is not a recall or a ban. European regulators reached a similar conclusion last year, calling NAION a "very rare" side effect of semaglutide. Analysts who follow these medications expect most people to keep taking them, because the benefits — weight, blood sugar, heart, kidney — are substantial.
What this means for you
Don't stop your medication over a headline. If the news worries you, that's a conversation for your prescriber, who knows your history. Stopping suddenly, on your own, trades a rare and unproven risk for the very real return of the conditions the medication is treating.
Do put your eyes on your checklist. Whether or not this warning existed, a baseline eye exam when you start a GLP-1 — and regular follow-ups after — is simply good care on this journey. Rapid changes in blood sugar can affect the eyes on their own; your eye doctor can only help with what they can see.
And know the one symptom that can't wait: a sudden change in vision — a shadow, a dimming, vision loss in one eye — is a same-day phone call to an eye doctor, not a wait-and-see. That was true before this week, and it's the most useful thing this news can remind any of us.
Where we stand — plainly
We are Selah Nutraceuticals, and we make Selah Sight, a formula of everyday eye-health nutrients created for people on the GLP-1 journey. So let us be as plain with you as we know how:
Selah Sight is not a treatment for NAION, and it is not proven to prevent it. No supplement is. Anyone who tells you otherwise is selling you something you should not buy. What Sight is built to do is more ordinary and, we think, still worthwhile: provide daily nutritional support for macular health and help with eye strain from blue light — the everyday side of eye health, which matters more, not less, when you're paying attention to your eyes.*
The most protective thing you can do for your vision on this journey isn't in a bottle. It's an eye exam. Keep yours. We'll keep making the daily support — and praying over every bottle before it ships.
— Joseph & Alexis Eggleston, Selah Nutraceuticals, Fort Worth, Texas
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is educational and is not medical advice; talk with your own doctor about your medications and your eyes.
Source: U.S. Food and Drug Administration labeling action as reported by CNBC, November 10, 2026.
Every Selah order is prayed over before it ships — blessed for the person receiving it and the journey they're on. Soli Deo Gloria.